SS31

As research shows

SS‑31 (elamipretide) is a mitochondria‑targeted tetrapeptide that selectively binds cardiolipin in the inner mitochondrial membrane, stabilizing electron transport chain complexes and reducing reactive oxygen species production while enhancing ATP synthesis. This peptide has demonstrated protective effects in preclinical models of heart failure, neurodegenerative disease, and age‑related muscle atrophy, and received FDA accelerated approval in 2025 as the first treatment for Barth syndrome

key benefits

• Stabilizes mitochondrial membranes and optimizes electron transport chain function
• Enhances ATP production and reduces pathological reactive oxygen species in metabolically active tissues
• Demonstrated functional improvements in Barth syndrome patients (increased muscle strength, improved exercise capacity)
• Shows protective effects in preclinical models of heart failure, neurodegenerative disease, and age‑related muscle atrophy
• Does not significantly alter blood pressure, heart rate, or standard laboratory parameters in clinical trials